Article : ACAD WILL CONTINUE TO RISE- Drug Looks Set For APPROVAL ((( link )))
Seeking Alpha - 3/26/13 - By: Matthew Smith - Stocks Making moves
Shareholders in Acadia Pharmaceuticals (ACAD) saw shares rise strongly again on Monday as more positive comments trickled out from the analyst community. Shares rose $0.74 (9.78%) to close at $8.31/share on volume of 7.9 million shares after an analyst at Jefferies, Thomas Wei, reiterated his 'Buy' rating on the stock and the $13/share price target he has on it. They think that the drug gets approval and after speaking to the medical community they feel that the results really were as good as they were perceived to be. As we said last week, this is a story which will continue to get better and can be traded moving forward.. We should see a continued rise as the company's drug looks set for approval.
Analysts: CBS May Buy Back Shares and 4 More Research Notes to Review Now
By Leah Powell | More Articles
March 14, 2013
Page 1 of 5
Acadia Pharmaceuticals (NASDAQ:ACAD): Roth Capital is convinced that a Phase III trial of ACADIA’s
pimavanserin for psychosis in Parkinson’s disease showed strong efficacy results supporting the $1 billion potential for the drug. The firm keeps its Buy rating and an $11 price target on the stock.
Yahoo News March 15, 2013 ( Friday )
FDA's New "Breakthrough" Designation Allows New Drugs to Gain Approval After Just 1 Round of Testing
Five Star Equities Provides Stock Research on ACADIA Pharmaceuticals and BioCryst Pharmaceuticals
The FDA's new "breakthrough" product designation allows new drugs to win approval after just a single round of testing, instead of the usual three. A total of three promising experimental medicines have been assigned the new status so far, while an additional 18 drugs have applied. The new designation follows three other programs -- Fast Track, Priority Review and Accelerated Approval -- each of which were designed to help bring crucial new drugs to market in a shorter amount of time.
"A breakthrough drug is one that may offer important new benefits for patients with serious or life-threatening disease who are especially in need of new safe and effective treatments," said Janet Woodcock, director of FDA's Center for Drug Evaluation and Research.
Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns
ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.
Glaxo May Buy Theravance to Gain New Drugs, Piper Analysts Say
By Makiko Kitamura - Mar 4, 2013
GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, may consider acquiring Theravance Inc. (THRX) to fully control respiratory drugs the companies developed together, analysts said.
The Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee will review the two companies’ Breo drug on March 7. Glaxo currently owns 27 percent of Theravance and may pay $51 a share for the remainder, Piper Jaffray analysts said in a note to investors. That’s more than double the closing price on March 1 and would value the remaining stake at about $3.6 billion